REG - ReNeuron Group plc - Directors' Interest in Shares and Share Options <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

02/10/2015 15:00

RNS Number : 1172B
ReNeuron Group plc
02 October 2015
2 October 2015
AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
Directors' Interest in Shares and Share Options 
Guildford, UK, 2 October 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces that on 1 October 2015, the following awards were made under the Company's share-based Long Term Incentive Plan (LTIP):

LTIP: number of shares awarded
Total shares over which options are held 
Percentage of issued shares under option




Olav Helleb 
18,123,636
33,679,192
1.07%
Michael Hunt
 7,090,909
29,611,692
0.94%




The LTIP awards are share options granted at nominal value and are subject to a three-year holding period, exercisable from the third anniversary of the award. The options are exercisable subject to the achievement of the following performance conditions:
1) When the first patientisadministered with a ReNeuron cell therapy in a sixth clinical trial, one third of the options will vest. 
2) When the fourth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.
3) If the Total Shareholder Return (TSR) of the Companymeets or exceeds that of the FTSE AIM Healthcare Indexin any given three year period from the date of grant, one third of the options will vest. 
The vesting criteria for the TSR-related performance condition above will also apply on a proportionate basis to TSR-related performance conditions attaching to prior share option grants under the LTIP.
Enquiries:
ReNeuron
+44 (0) 20 3819 8400
Olav Helleb , Chief Executive Officer

Michael Hunt, Chief Financial Officer

Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson



Cenkos Securities
+44 (0) 20 7397 8900
Dr Christopher Golden,Stephen Keys (NOMAD and Broker)

Russell Kerr (Sales)

About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to enter the clinic in the US. 
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSXLLFBEBFEFBQ